ERIN FOX-HAMMEL: Open Payments
NPI 1609532373 · JOHNSTON, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$987 in 76 payments from 16 companies in 2025. Trend: 2023 $1,037 · 2024 $1,564 · 2025 $987
Food & beverage: $987
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $326 |
| ABBVIE INC. | 27 | $235 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Neurocrine BioSciences, Inc. | 3 | $58 |
| Corium, LLC | 4 | $57 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Neos Therapeutics, LP | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
Products named: VRAYLAR, REXULTI, ABILIFY MAINTENA, ABILIFY ASIMTUFII, INGREZZA, Azstarys, Auvelity, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
